Skip to main content

Biotech News

Latest coverage on Biotech from trusted news sources, updated throughout the day.

3 articles tracked2 sourcesLatest: Apr 7, 2026
biotechbiotechnologygene therapycrisprgenomicsbiologic

Recent Articles

Scientists develop gene-edited wheat that can make toasted bread less carcinogenic

Bread and biscuits made from Crispr-edited wheat showed substantially reduced acrylamide levels, even after toasting Gene-edited wheat which can make bread less carcinogenic when toasted has been successfully developed by scientists. Researchers at Rothamsted Research in Harpenden, Hertfordshire, used Crispr genome editing which allows researchers to selectively edit the DNA of living organisms. This revolutionary technology was adapted for use in the laboratory from naturally occurring genome e

World news | The Guardian

Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study - Bloomberg.com

Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study  Bloomberg.com Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial  CNBC Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes  Eli Lilly Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial  Fierce Biotech Lilly's next-gen obesity drug shows reduction in b

Top stories - Google News

Why This Biotech, Up 47%, Could Spark The Next Buyout Frenzy - Investor's Business Daily

Why This Biotech, Up 47%, Could Spark The Next Buyout Frenzy  Investor's Business Daily Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars  Fierce Biotech Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial  statnews.com Xenon gets Phase 3 win with epilepsy drug, fueling blockbuster hopes for its first launch  Endpoints News Worth the wait: Xenon’s azetukalner exceeds expectations in FOS  bioworld.com

Top stories - Google News

Related Topics

Get a personalized AI briefing on Biotech and more.

Try The Brief — free